The little Australian biotech firm that once counted U.S. Health and Human Services Secretary Tom Price as a shareholder — a link that roiled his Senate confirmation hearing last winter — is facing closure, the company has told shareholders.
Innate Immunotherapeutics will probably shut down in the coming months, CEO Simon Wilkinson said at the company’s annual meeting Wednesday, The Australian, a news outlet, reported.
